No. of Recommendations: 4
There is no confusion in many minds about the apparent avoidance of applying any tariffs on Russia, yet we are applying a 50% tariff on imports from India to punish them for doing business with Russia. Interesxtingly, China, Russia's largest trading partner, has not had any incremental penalty for this trade.
In fact, during the lead up meeetings to, and during the meeting between Putin and Trump in Alaska, the were negotiations to bring Exxon back to Sakalin Island in Eastern Russia (along with the purchased of drilling equipment) by Russia. I wouldn't be a bit surprised if there wasn't a discussion of a trade-off of Greenland for Ukraine (and that's why the large group of European VIP's rujshed to Washington to show their solidarity).
The Trump administration has said it will cut the prices Americans pay for presciption medications.
This doesn't make the task easier (from ChatGPT):
Key Figures
1. Generics Prescriptions Share
In 2022, Indian pharmaceutical companies accounted for 47% of all generic prescriptions dispensed in the U.S.
Business Standard
IBEF
.
Indian firms are the top suppliers in many therapeutic areas, including mental health (62%), hypertension (60%), lipid regulators (58%), anti-ulcerants (56%), and nervous system drugs (55%).
Business Standard
2. Generics Imports Share
According to a statement by an Indian health minister in 2025, 14% of generic drugs imported by the U.S. come from India
Business Standard
Outlook India
.
Note: This percentage refers specifically to imported generics, not the entirety of generic prescriptions, which often also include domestically manufactured drugs.
3. Active Pharmaceutical Ingredients (APIs)
India plays a major role in supplying APIs—the raw materials needed to make drugs. A U.S. Pharmacopeia (USP) analysis from 2025 reveals that generics (which make up 90% of U.S. prescriptions) rely heavily on India for APIs, though an exact percentage attributable solely to India wasn’t isolated from India+EU combined data
Quality Matters
.
Other research notes that as of 2024, India accounts for about 48% of API supply to the U.S., though this includes API for all prescription medicines—not just generics
Jeff
